BRIEF—Tricida first to report clinical trial delay due to Ukraine crisis

Shares of USA-based Tricida closed up 4.9% at $7.71 yesterday, despite becoming the first biotech to specifically state that at least part of a clinical study will be delayed due to the military conflict between Russian and Ukraine.

Tricida announced an update on the anticipated date for top-line data from the VALOR-CKD trial based on the ongoing events in Ukraine.

Around 15% of the patients randomized in VALOR-CKD are from Ukraine.

Given the uncertainty around future participation of Ukrainian subjects in the trial and the potential challenges to collecting and monitoring data from Ukrainian sites, top-line data from the VALOR-CKD trial is now anticipated early in the fourth quarter of 2022, versus Tricida’s previous guidance of the third quarter of 2022.

“We are deeply concerned for the people of Ukraine, including the VALOR-CKD patients, investigators, site staff and our CRO colleagues who we have worked with for many years. We are horrified by what they and all of the Ukrainian people are having to endure defending their homeland against a brutal Russian invasion,” said Gerrit Klaerner, Tricida’s chief executive and president.